Analysis of Trends Over Time of Hepatitis Related Incidence in Panama
Time Trend Analysis of the Incidence of Hepatitis- Related Outcomes (Viral Hepatitis A and Unspecified Viral Hepatitis) Reported to the Surveillance System of Panama, 2000-2010
1 other identifier
observational
1
1 country
1
Brief Summary
The purpose of this study is to analyze the incidence of baseline hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) together with the current frequency of the same outcome after introduction of Havrix™ in Panama.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jan 2009
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2009
CompletedFirst Submitted
Initial submission to the registry
July 8, 2010
CompletedFirst Posted
Study publicly available on registry
July 12, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2011
CompletedJune 7, 2017
June 1, 2017
2.6 years
July 8, 2010
June 6, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Occurrence of reported hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis)
In post vaccine introduction period (2008-2010) compared to pre-vaccination period (2000-2007)
Secondary Outcomes (3)
Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by year
From year 2000 until year 2010
Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by age groups
From year 2000 until year 2010
Occurrence of hepatitis related outcomes (viral hepatitis A and unspecified viral hepatitis) by region
From year 2000 until year 2010
Study Arms (1)
Hepatitis Cohort
Subjects suffering with hepatitis
Interventions
Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
Eligibility Criteria
The target population to be studied will be all subjects reported with hepatitis related outcomes to the Epidemiologic Surveillance System of the Ministry of Health of Panama, between 2000 and 2010.
You may qualify if:
- Hepatitis related outcomes occurred during the period analyzed and registered in the Epidemiologic Surveillance System of the Ministry of Health, will be collected for the study
You may not qualify if:
- Not applicable
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- GlaxoSmithKlinelead
Study Sites (1)
GSK Investigational Site
Clayton, Provincia de Panamá, Panama
Related Publications (1)
Estripeaut D, Contreras R, Tinajeros O, Castrejon MM, Shafi F, Ortega-Barria E, DeAntonio R. Impact of Hepatitis A vaccination with a two-dose schedule in Panama: Results of epidemiological surveillance and time trend analysis. Vaccine. 2015 Jun 22;33(28):3200-7. doi: 10.1016/j.vaccine.2015.04.100. Epub 2015 May 14.
PMID: 25981490DERIVED
Biospecimen
No samples retained
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
GSK Clinical Trials
GlaxoSmithKline
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 8, 2010
First Posted
July 12, 2010
Study Start
January 1, 2009
Primary Completion
August 1, 2011
Study Completion
August 1, 2011
Last Updated
June 7, 2017
Record last verified: 2017-06